Compare Deckers Outdoor Corp (DECK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Incyte Corporation — how do they compare? Deckers Outdoor Corp trades at $82.76 (market cap $11.24B), while Incyte Corporation trades at $113.3 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 2× Deckers Outdoor Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Incyte Corporation for 33 Days on average.
| DECK | INCY | |
|---|---|---|
Market Cap | $11.24B | $22.85B |
Volume | 3,010,945 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $129.93 |
52-Week Low | $77.51 | $83.80 |
Typical Hold Time | 71 Days | 33 Days |
Enterprise Value | $10.11B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.15, up 2.2% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats, 19.4% net margin, and robust revenue growth from $3.2B in 2022 to $5.0B in 2025. Recent news highlights HOKA and UGG brand momentum driving investor optimism. Technical indicators show the stock trading near resistance at $82 with support at $79.
DECK presents compelling value with a P/E of 11.7x below industry averages and analyst consensus target of $117 suggesting 43% upside. Risks include competitive pressures in footwear and potential macroeconomic headwinds affecting consumer discretionary spending. The strong cash flow generation and brand strength support continued growth potential.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
